COVID-19 has created a defining moment for the life sciences sector. Investors, executives and advisors will come together to explore life science investing, deal trends, emerging areas of disruption, regulatory developments, and an outlook for 2022 and beyond.
Goodwin's Life Sciences and FDA partner, Julie Tibbets, will be moderating the 12 pm EST panel, "State of Life Sciences: Has Drug Development Changed Forever?" along with Ellen Lubman of Werewolf Therapeutics, Ritika Mahal of Bain Capital and Uciane Scarlett of MPM Capital.
For more information on the forum including speakers and a full agenda, click here.Register